HCV
AbbVie hep C treatment fast-tracked
June 18, 2014Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi
The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …
Merck buys Idenix
June 10, 2014Manufacturing and Production, Sales and Marketing HCV, IDX21437, IDX21459, Merck, hep C, idenix
Merck is to improve its pipeline of hepatitis C virus (HCV) treatments by splashing out $3.85 billion on biopharma firm …
Sovaldi performs for Gilead
April 24, 2014Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …
Europe nod for Gilead HCV pill
January 20, 2014Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …
BMS files oral hep C treatment
November 5, 2013Sales and Marketing BMS, HCV, dvc, hep C
Bristol-Myers Squibb has filed its investigational hepatitis C treatment – the first oral regime without interferon or ribavirin – with …
Janssen takes on GSK hep C drug
October 9, 2013Research and Development, Sales and Marketing GSK, GSK2336805, HCV, Janssen
Janssen Pharmaceuticals has acquired one of GlaxoSmithKline’s investigational hepatitis C treatments and will look at it in combination with various …
High cure rate for Boehringer HCV drug
June 11, 2013Research and Development, Sales and Marketing Boehringer Ingelheim, HCV
One of Boehringer Ingelheim’s pipeline drugs has achieved high response rates in patients with chronic genotype-1 hepatitis C virus (HCV) in …
HCV agreement for Merck and BMS
April 23, 2013Research and Development, Sales and Marketing BMS, HCV, Merck
Merck & Co and Bristol-Myers Squibb have signed a non-exclusive agreement to conduct a Phase II trial looking at a …
Patient death halts BMS hep C trial
August 30, 2012Sales and Marketing BMS, HCV, hepatitis C
Bristol-Myers Squibb has admitted that the death of a patient was behind its decision to stop development of a potential …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Boehringer hails hepatitis C candidate
November 9, 2011Sales and Marketing BI201335, Boehringer Ingelheim, HCV, Incivo, Victrelis, hepatitis C
Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …
New hepatitis C drug offers cure for more patients
December 17, 2010Research and Development, Sales and Marketing HCV, Janssen, hepatitis C, liver disease, telaprevir
A new treatment from Janssen which could help cure many more patients with hepatitis C has been submitted in Europe. …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
